Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.

[Back to Overview]  [IACM Homepage]

TitleDelta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation.
Author(s)Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I, Simon RM, Rosenberg SA.
Journal, Volume, IssueAnnals of Internal Medicine 1979;91:819-824.
Major outcome(s)14 of 15 patients had decreased vomiting and nausea
IndicationNausea/vomiting;Cancer;Cancer chemotherapyAbstract

Fifteen patients with osteogenic sarcoma receiving high-dose methotrexate
chemotherapy were studied in a randomized, double-blind, placebo-controlled
trial of oral and smoked delta-9-tetrahydrocannabinol (THC) as an antiemetic.
Each patient served as his or her own control. Fourteen of 15 patients had a
reduction in nausea and vomiting on THC as compared to placebo.
Delta-9-tetrahydrocannabinol was significantly more effective than placebo in
reducing the number of vomiting and retching episodes, degree of nausea,
duration of nausea, and volume of emesis (P less than 0.001). There was a 72%
incidence of nausea and vomiting on placebo. When plasma THC concentrations
measured less than 5.0 ng/mL, 5.0 to 10.0 ng/mL, and greater than 10.0 ng/mL,
the incidences of nausea and vomiting were 44%, 21%, and 6%, respectively.
Delta-9-tetrahydrocannabinol appears to have significant antiemetic properties
when compared with placebo in patients receiving high-dose methotrexate.

Dose(s)10mg/m2 oral, 17mg smoking every 3 hours
Duration (days)
Participants15 patients receiving high-dose methotrexate
DesignControlled study
Type of publication
Address of author(s)
Full text

[Back to Overview]  [IACM Homepage]